Fig. 3.

Decreased bladder capacity and void volume in control rat following intravesical administration of a TRPV4 agonist. Representative cystometrogram recordings of effects of a TRPV4 agonist (GSK1016790A) in a control (no RVS) rat using continuous intravesical infusion of saline. Pre-GSK1016790A (A) and post-GSK1016790A (B) bladder function traces in a control rat that has not been exposed to 7 d of RVS are shown. TRPV4 receptor activation with intravesical infusion of GSK1016790A (3 μM) decreased both bladder capacity (measured as the amount of saline infused in the bladder at the time when micturition commenced) and void volume compared with pretreatment conditions. Infused volume (ml, top), bladder pressure (kPa, middle), and void volume (ml, bottom) are shown in A and B, which were recorded from the same rat.